Chauvin sales rise thanks to foreign acquisitions:
This article was originally published in Clinica
Executive Summary
Sales at French ophthalmology company Chauvin were up 68% to Fr 582 million ($120 million) in 1994 compared with the previous year. This includes sales from Smith & Nephew's (UK) ophthalmic division and Ankerpharm (Germany), which Chauvin purchased last year. Excluding these, sales were up 12.5% on 1993 figures. Consolidated profits remained flat at Fr 36 million. Excluding goodwill amortisation of the acquisitions, net profit rose 41% to Fr 52 million. Foreign sales increased during the year, with almost half the company's revenues coming from outside France, compared with just 20% in 1991. Chauvin expects a 5% growth in turnover in 1995.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.